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2018). Here, we present the study design of a phase 3 trial of cabozantinibþ atezolizu-
mab vs sorafenib in patients with aHCCwho have not received prior systemic therapy.
Methods: This international, randomized, open-label phase 3 trial (NCT03755791) is
evaluating the efficacy and safety of cabozantinibþ atezolizumab vs sorafenib as first-
line treatment for aHCC. Eligibility criteria include age18 years, BCLC stage B or C,
Child-Pugh A, ECOG PS 0 or 1, andmeasurable disease per RECIST 1.1. Patients are
randomized 6:3:1 to an experimental arm of cabozantinib (40mg qd)þ atezolizumab
(1200mg infusion q3w), a control arm of sorafenib (400mg bid), and an exploratory
arm of cabozantinib monotherapy (60mg qd). 640 patients are planned at200 sites
globally. Randomization is stratified by disease etiology (HBV [with or without HCV],
HCV [without HBV], or other), region (Asia, other), and the presence of extrahepatic
disease and/or macrovascular invasion (yes, no). OS and progression-free survival are
co-primary endpoints and objective response rate is a secondary endpoint. Additional
endpoints include safety, pharmacokinetics, and correlation of biomarker analyses
with clinical outcomes. Enrollment in COSMIC-312 is ongoing.
P 239 Sorafenib for advanced hepatocellular carcinoma (HCC) in the
public health setting in Brazil: a cost-effectiveness analysis
A Sasse1, R Carmo2
1CEVON - Centre for Evidence in Oncology - UNICAMP - State University of Campinas,
Campinas, Brazil, 2SOnHe, Campinas, Brazil
Introduction:Hepatocellular carcinoma (HCC) has a high incidence andmortality
worldwide. Until 2007, there were no drugs that could increase the overall survival in
advancedHCC patients. Sorafenib remains the standard-of-care in first-line setting since
then. The survival benefit of sorafenib is accompanied by its high cost. All over the world,
there has been an increasing discussion on treatment costs and the sustainability of health
care systems. In Brazil, the government health expenditures for the public health system
have not been sufficient to ensure adequate service for the population and sorafenib is not
available in this setting. Therefore, this study aimed to assess the cost-effectiveness of sora-
fenib for advancedHCC in the public health system in Brazil.
Methods: A systematic review of the literature was performed in order to identify the
best evidence of sorafenib against placebo and/or best supportive care in advanced
HCC. The search strategy retrieved 443 articles in Pubmed and EMBASE platforms and
441 were excluded after thourough analysis. The remaining two studies were SHARP
trial and ASIA-PACIFIC trial. As the Brazilian population is more similar to the one of
SHARP and also because this study is larger, it was selected for the analysis. The data on
efficacy and safety were extracted. Cost of sorafenib and costs related to usual medical
care were taken from governmental sources. After all the data were gathered, the analy-
sis was performed with the software Treeage Pro Suite 2017 using theMarkov model
for simulating the possible health states of HCC patients (Sorafenib, best supportive
care or death). The primary outcome was the Incremental Cost-Effectiveness Ratio
(ICER). As the Brazilian government does not define a cost-effectiveness threshold, we
used the OMS-suggested 3 times the Gross Domestic Product (GDP), that is,
US$29.464,23. The discount rate was set to 5% and the time horizon, 10 years.
Afterwards, a sensitivity analysis was conducted to determine the most contributable
factors to ICER value.
Results: The estimated effectiveness of sorafenib yielded a median overall survival of
14,4 months, while the best supportive care (BSC) group was 9,24 months, leading to
an incremental effectiveness of 5,16 months. The average cost per patient who received
sorafenib was US$14.013,76, while the cost for BSC group was US$447,10. The ICER
was US$31.793,21, which surpassed the threshold in 8%. In the sensitivity analysis, the
most important factor that contributed to the ICER was the cost of sorafenib.
Conclusion: Sorafenib was not considered cost-effective for advancedHCC patients in
the Brazilian public health systemwhen compared to BSC. Nevertheless, the difference
was small and the drug could be considered for incorporation in this setting after a price
negotiation with the healthcare industry, once the latter has already offered a 26% dis-
count in another study. Moreover, at this time, these advancedHCC patients have no
treatment available for their disease.
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Introduction: The first in human Phase 1 Program at the University of Alabama at
Birmingham offers novel experimental options to cancer patients. A total of 303
patients were enrolled in phase 1 trials between 2015 – 2018.We review and present the
clinical course specifically of the 55 patients (18%) with gastrointestinal tumors
enrolled during this period.
Methods: 55 cancer patients (whole cohort, WC)met eligibility and were enrolled on
phase 1 studies and received either a targeted therapy (TT) alone or in combination
with immunotherapy (IOT).We assessed the relationship between clinical characteris-
tics and clinical outcomes, including 90-day mortality (90DM) and clinical benefit rate
(Complete responseþ partial responseþ stable disease) using univariate andmulti-
variate logistic regression.
Results:Of theWC, 31 (56%) patients received at least one cycle of TT alone and 24
(44%) patients received IOT alone or in combination with another therapy. Table 1
provides key characteristics of theWC population. Median age was 57 years, 81.8%
were Caucasians and 60.0%were men. A total of 26 (47.3%) patients underwent Next
Generation Sequencing and 4 (7.3%) of them demonstrated actionable mutation. Of
theWC, 35 (63.6%) had received>2-4 prior therapies and 10 (18.2%)>¼ 5 prior
therapies. Overall, Grade 3 or 4 events were observed in 45% (WC) vs 51% (TT) vs 40%
(IOT). The 90DMwas 20% (WC) vs 19.4% (TT) vs 20.8% (IOT). The clinical benefit
rate was 36.4% (WC) vs 32.3% (TT) vs 41.7% (IOT). The median time to treatment
failure form the administration of at least one cycle of study treatment was 2.3 m (WC)
vs 2.5 m (TT) vs 2.1m (IOT).We could determine no statistically significant association
between clinical characteristics and clinical benefit rate or 90DM.
Conclusion:We present outcomes data specifically related to a subset of patients with
GI tumors enrolled on our TT or IOT phase 1 studies. Our data reflects the new trends
in precision medicine with an increasing proportion of patients are receiving TT or
IOT as part of Phase 1 trials. The outcome of our cohort accrued between 2015 – 2018
appears comparable to the previously published data for the total cohort of phase 1
patients, indicating that patients with GI tumor fare no differently than other cancer
patients when it comes to phase 1 trials. The lack of predictive association between
treatment and outcomemay well be related to the small sample size (n¼ 55), heavily
pretreated patients (80% received>2 prior therapies) and the lack of phase 1 studies
that specifically targeted GI-tumor associated biomarkers or pathways. This empha-
sizes the need to develop biomarker enriched study designs and to consider phase 1
clinical trials earlier, rather than later for improved outcomes.
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Introduction:Gallbladder cancer is the most commonmalignant tumor of the biliary
tract and the fifth most common amongmalignant neoplasms of the digestive tract. Its
diagnosis, often late, is most often done at a stage of non-resectability.
Methods: The objective of this study was to focus on different epidemiological, clinical,
paraclinical and prognostic aspects of this pathology. In this retrospective study, we
reported on 96 cases of gallbladder cancer gathered in the department of medical oncol-
ogy EHS-LCC Blida-Algeria between January 2011 and December 2016.
Results: The average age of patients was 61.5 years ranging from 42 to 84 years. There is
a female predominance (72% of cases). Family history of cancer was 18.7%, 34% had
diabetes and 43% had hypertension in their antecedents; tobacco smoking was present
in 26.5% of cases. History of gallstones was present in 23% of cases. The clinical symp-
tomatology was dominated by pain in the right upper quadrant (85.5% of cases), vom-
iting (8% of cases) and jaundice (3% of cases). Average time for consultation was 4.5
months. The histological type was adenocarcinoma in 94.7% of patients, with stage IV
and III in 93.7% and 4.7% of patients at diagnosis, respectively.
Conclusion: The diagnosis of cancer of the gallbladder is made at a late stage, as the dis-
ease becomes symptomatic, which is a testament to the gravity of this cancer. To
improve this situation, prevention and acting on risk factors has an important place.
Around the world, significant efforts are being made in order to better understand gall-
bladder cancer. Detailed epidemiological analyses of gallbladder cancer trends and fur-
ther analytical epidemiological research will help guide future cancer control strategies.
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Introduction:Oral mucositis (OM) is an inflammation of the oral mucosa affecting
around 20 to 40% of patients on conventional chemotherapy (CM).Many agents have
been tried to treat it with different results. However, prevention is more important. We
have recently published good results with a combination mouthwash applied before
the expected OM appears in patients with breast cancer undergoing neoadjuvant or
adjuvant chemotherapy. Then, we decided to evaluate this mixture in patients receiving
FOLFIRINOX in pancreatic carcinoma and those receiving FOLFOX or FOLFIRI in
colorectal cancer.
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Methods: Prospective study of pancreatic cancer patients undergoing neoadjuvant or
palliative therapy with FOLFIRINOX (5 fluorouracil, oxaliplatin, irinotecan) and col-
orectal cancer patients under FOLFOX (5 fluorouracil, oxaliplatin) or FOLFIRI (5 fluo-
rouracil, irinotecan) who developed OM grade 2 or 2-3 with the previous cycle. We
used the same combination with a higher dose of Prednisolone and Nystatin before
considering any CM dose reduction (DR). It consisted of 100mL of water combined
with 30mg of soluble prednisolone, 6 drops of nystatin and 2.300mg of salt (1 tea-
spoon). Patients were educated clearly on how to use it. Primary end-point was the
incidence of OM grade 2-3 with the following cycle and secondary end-points were rate
of CMDR and the incidence of OM grade 0, 1 and 2 with the next cycle.
Results: Thirty-five patients were included. 21 had developed OM grade 2-3 with prior
cycle and 14 grade 2. After using this mouthwash, no cases developed grade 2-3 OM
and none needed a DR due to OM. Ten patients developed OM grade 2 which recov-
ered quickly to grade 1. Sixteen patients grade 1 OM and the rest no OM (grade 0).
Conclusion: This study shows a significant reduction in the rate of OM grade 2-3 in
patients using this mixture as mouthwash. Although further evaluation is needed to
confirm its final benefits we use this as standard in our institution.
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Introduction: A standard treatment recommendation for advanced stage gastroeso-
phageal cancer is still missing. In this retrospective study, we evaluated the survival rates
of different palliative treatment strategies.
Methods:We analyzed clinical data including therapies, human epidermal growth fac-
tor 2 (HER2) status, toxicities, tumor markers, and survival of patients with inoperable
locally advanced or metastatic gastroesophageal cancer treated between 2001 and 2017
at the Vienna General Hospital, Austria.
Results: In total, the survival outcome of 244 patients was evaluated. Administration of
systemic therapy was positively associated with overall survival (OS) (469 days vs. 185
days; P< .001), while palliative gastrectomy or radiotherapy showed no correlation
with OS. There was no difference in OS in cisplatin/5-FU vs. oxaliplatin/5-FU
(FOLFOX). OS was significantly longer in patients receiving capecitabine/oxaliplatin
(XELOX) vs. FOLFOX (600 days vs. 327 days, P< .05). Comparison of doublet vs. trip-
let chemotherapies showed no difference in OS. Further analysis demonstrated no dif-
ference in docetaxel/cisplatin/5-FU (DCF) vs. docetaxel/oxaliplatin, in DCF vs.
cisplatin/5-FU or in epirubicin/oxaliplatin/capecitabine vs. XELOX. The anti-HER2-
antibody trastuzumab doubled OS (836 days vs. 399 days, P¼ .053). Triplet chemo-
therapy resulted in more adverse events than doublet chemotherapies.
Conclusion: In this retrospective analysis, we documented OS differences between
patients treated with and without systemic therapy and between patients treated with
various systemic agents. Our data support the preferred use of capecitabine over
infused 5-FU and doublet chemotherapy over triplet chemotherapy in the first-line pal-
liative setting of advanced/metastastic gastroesophageal cancer.
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Introduction:Gallbladder cancer is the most commonmalignant tumor of the biliary
tract and the fifth most common amongmalignant neoplasms of the digestive tract. Its
diagnosis, often late, is most often done at a stage of non-resectability.
Methods: The objective of this study is to make focus on different epidemiological,
clinical, paraclinical and prognosis aspects of this pathology. In this retrospective study,
we report 96 cases of gallbladder’s cancer gathered in the Department of medical oncol-
ogy EHS-LCC Blida-Algeria between January 2011 and December 2016.
Results: The average age of patients was 61.5 years ranging from 42 to 84 years. There is a
female predominance (72% of cases). Family history of cancer was 18.7%, 34%had diabe-
tes and 43% had hypertension in their antecedents; tobacco smoking was present in
26.5% of cases. The gallstone is present in 23% of cases. The clinical symptomatology is
dominated by pain of the right upper (85.5% of cases), vomiting (08% of cases) and jaun-
dice (3% of cases), average time for consultation is 4.5months. The histological type was
adenocarcinoma in 94.7% of patients, stage IV and III in 93.7% and 4.7% at diagnosis
Conclusion: As the cancer of gallbladder becomes symptomatic the diagnosis is made
with a late stage, which testifies to the gravity of this cancer, to improve this situation
prevention keeps an important place by acting on the risk factors. Around the world,
significant efforts are being made in order to better understand gallbladder cancer.
Detailed epidemiological analyses of gallbladder cancer trends and further analytical
epidemiological researches will help guide future cancer control strategies.
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Introduction:Optimal treatment strategy beyond systemic chemotherapy for locally
advanced pancreatic cancer (LAPC) remains undefined. Stereotactic Body Radiation
Therapy (SBRT) improves local control and is emerging as a potential treatment for
pancreatic cancer; however, there is limited data on the optimal sequence, safety, and
efficacy of combination chemotherapy and SBRT in the neoadjuvant setting. Potential
benefits of 5-fraction SBRT include greater local control of tumor and lesser interrup-
tion to effective systemic therapies. Sequencing SBRT following 2months of chemo-
therapy helps to initiate early treatment for micrometastases and to exclude patients
who declare metastases despite early chemotherapy. In our study, SBRT is planned to
follow chemotherapy, provided toxicity has resolved to grade 2 or less. Concurrent che-
motherapy is not administered along with SBRT.
Methods: Primary outcomemeasured is the safety and tolerability associated with neo-
adjuvant chemotherapy followed by SBRT in LAPC. Patients diagnosed with LAPC
(borderline resectable or unresectable), ECOG 0-2 will be assigned to one of two treat-
ment arms, either FOLFIRINOX or gemcitabine and nab-paclitaxel based on functional
assessment. After two cycles (2 months) of treatment, patients will be re-staged with CT
imaging and SBRT will be administered if they convert to resectable or remain stable
without distant progression. SBRT will be delivered to the tumor and planning target
volume (PTV) to 33Gy (6.6 Gy x 5 fractions) on a linear accelerator using volumetric
modulated arc therapy (VMAT). During SBRT image guidance will be employed
through the use of fiducials and kV imaging. Respiratory motion will be corrected using
breath-hold or respiratory gating techniques. Patients without progression will
undergo surgery 4-6 weeks following SBRT. Borderline or unresectable patients were
permitted to resume chemotherapy one-week post-SBRT. 17 patients (planned sample
size, n¼ 30) have been enrolled thus far. This trial evaluates tumor and circulating free
DNA for mutations relevant to pancreatic cancer to assess for variations among res-
ponders and non-responders. In addition, one tumor tissue sample at the time of diag-
nosis, four plasma samples at specified time points, one tumor tissue sample in patients
who undergo surgical resection, and an optional tumor tissue sample from themeta-
static site and plasma sample will be collected at disease progression. This study utilizes
the University of Alabama at Birmingham (UAB), O’Neal Comprehensive Cancer
Center Data and Safety Monitoring Plan and is registered at clinicaltrials.gov,
NCT03600623
Results: 17 patients enrolled.
Conclusion: This study is currently enrolling actively.
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Introduction: The differentiation between the right colon (RC) and left colon (LC)
cancer with the splenic angle or the 1/3 distal transverse colon as an anatomic reference
was recently debated. It was discussed because of its distinct embryologic differentia-
tion, anatomy, microbiome, biliary acid levels, different molecular patterns, different
risk factors, histology and way of disease dissemination. The LC is associated with bet-
ter prognosis and a better response to EGFR inhibitors in patients with RAS wild type.
The objective of the study is to analyze the differences between RC and LC stage IV dis-
ease at our institution.
Methods: A retrospective study with revision the patients with stage IV colon cancer
treated with a systemic treatment at our department between January/2011 and
December/2017. It was excluded rectal cancer (when the primary tumor was distal to
15 cmof anal verge), patients with synchronous tumors andwhen the important informa-
tion is lack. RCwas defined when the primary tumor was located between the cecum and
transverse colon and LCwhen the lesion was between the splenic angle and the distal sig-
moid colon. Statistical analysis using SPSSwith a survival analysis (Kaplan-Meier, Log
Rank, statistically significance 5%)was donewith follow up until 31/01/2019.
Results: It was analyzed 95 patients, 42 (44,2%) with RC and 53 (55,8%) with LC can-
cer. Synchronous metastasis was present in 55 (57,9%) of the population. Liver meta-
static disease was 77,4% (n¼ 41) in patients with LC versus 64,3% (n¼ 27) in patients
with RC cancer, p¼ 0,161. Sixty patients (63,2%) were submitted to 2nd line therapeu-
tic and 31,6% (n¼ 30) to a 3rd line or beyond systemic treatment. With a median fol-
low up period of 53,5 months (mo.) and 58 (61,1%) events, the median overall survival
(OS) was 25,8mo. (CI 95% 23,46 – 28,14). The OS in RC cancer was 25,1mo. (CI 95%
19,23-30,97) versus 26,8mo. (CI 95% 20,45-33,15) in LC cancer, p¼ 0,268. Analyzing
the first line systemic therapeutic in the following 3 subgroups: (1) patients submitted
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